Heart Rhythm Study Shows CardioFocus Inc. HeartLight EAS Provides Durable Pulmonary Vein Isolation in Treatment of Atrial Fibrillation

Published: Jun 18, 2012

Unique Remapping Study Finds 86% of PVs Remained Electrically Isolated and Notes Physician Learning Curve of Only 10 Cases CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that a unique study in the journal Heart Rhythm demonstrates high acute success (98%) and durable pulmonary vein (PV) isolation rates achievable with a single, visually-guided HeartLight EAS ablation procedure. To determine durability, the study involved a subsequent diagnostic remapping procedure that found 86% of PVs remained electrically isolated after three months. The multicenter study, authored by Srinivas R. Dukkipati, MD, Mount Sinai School of Medicine, New York, is published in the June 2012 issue.

Back to news